Financiado en parte por Canola Council of Canada, Flax Council of Canada, Dow AgroSciences, Dow Agrosciences
DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial
Jones PJ, Senanayake VK, Pu S, Jenkins DJ, Connelly PW, Lamarche B, Couture P, Charest A, Baril-Gravel L, West SG, Liu X, Fleming JA, McCrea CE, Kris-Etherton PM
The American journal of clinical nutrition · 73 citas
Etiquetas de revisión
Alimentación controladaFinanciado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- Comida provista por los investigadores
Quién lo pagó
- Financiación
- Financiado por la industria
- Grupo de la industria
- Canola Council of Canada
- Grupo de la industria
- Flax Council of Canada
- Gobierno
- National Institutes of Health
- Empresa
- Dow AgroSciences
- Gobierno
- Agriculture and Agri-Food Canada
- Gobierno
- National Center for Research Resources
- Gobierno
- National Center for Advancing Translational Sciences
- Grupo de la industria
- Canada Research Chairs, and Western Grains Research Foundation
- Gobierno
- NCRR NIH HHS
- Gobierno
- Agriculture and Agri Food Canada
- Gobierno
- NCATS NIH HHS
- Empresa
- Dow Agrosciences
- Gobierno
- NIH
- Subvenciones
- National Center for Advancing Translational Sciences (UL1-TR000127); National Center for Research Resources (UL1 RR033184)
Según 13 financiadores declarados.
Publicación
- Publicado
- 2014-05-15 · Am J Clin Nutr · vol. 100 · número 1 · págs. 88–97
- Editorial
- Elsevier BV
- Citado
- 115 citas · más que el 99% de estudios similares · 9.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 46 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Edible Oils Quality and Analysis · Nutritional Studies and Diet
- Palabras clave
- docosahexaenoic acid, dietary fatty acid composition, lipid profile, cardiovascular risk, coronary heart disease risk, abdominal obesity, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, omega-3 fatty acids, omega-6 fatty acids, omega-9 fatty acids
- MeSH
- humans, cardiovascular diseases, dietary carbohydrates, dietary fats, corn oil, docosahexaenoic acids, safflower oil, fatty acids, monounsaturated, oleic acid, triglycerides, dietary proteins, body mass index, treatment outcome, diet, risk factors, cross-over studies, double-blind method, blood pressure, adult, middle aged, female, male, cholesterol, ldl, cholesterol, hdl, waist circumference, rapeseed oil
14 autores
- Peter J.H. Jones🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Vijitha K. Senanayake🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Shuaihua Pu🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- David J.A. Jenkins🇨🇦🇺🇸St. Michael's Hospital; Pennsylvania State University; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Philip W. Connelly🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Benoı̂t Lamarche🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Patrick Couture🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Amélie Charest🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Lisa Baril‐Gravel🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Sheila G. West🇨🇦🇺🇸St. Michael's Hospital; Pennsylvania State University; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Xiaoran Liu🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Jennifer A Fleming🇨🇦St. Michael's Hospital; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Cindy E McCrea🇨🇦🇺🇸St. Michael's Hospital; Pennsylvania State University; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
- Penny M. Kris‐Etherton🇨🇦🇺🇸St. Michael's Hospital; Pennsylvania State University; University of Toronto; Université Laval; Institut sur la nutrition et les aliments fonctionnels (INAF); University of Manitoba
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
It is well recognized that amounts of trans and saturated fats should be minimized in Western diets; however, considerable debate remains regarding optimal amounts of dietary n-9, n-6, and n-3 fatty acids.
Objective
The objective was to examine the effects of varying n-9, n-6, and longer-chain n-3 fatty acid composition on markers of coronary heart disease (CHD) risk.
Design
A randomized, double-blind, 5-period, crossover design was used. Each 4-wk treatment period was separated by 4-wk washout intervals. Volunteers with abdominal obesity consumed each of 5 identical weight-maintaining, fixed-composition diets with one of the following treatment oils (60 g/3000 kcal) in beverages: 1) conventional canola oil (Canola; n-9 rich), 2) high-oleic acid canola oil with docosahexaenoic acid (CanolaDHA; n-9 and n-3 rich), 3) a blend of corn and safflower oil (25:75) (CornSaff; n-6 rich), 4) a blend of flax and safflower oils (60:40) (FlaxSaff; n-6 and short-chain n-3 rich), or 5) high-oleic acid canola oil (CanolaOleic; highest in n-9).
Results
One hundred thirty individuals completed the trial. At endpoint, total cholesterol (TC) was lowest after the FlaxSaff phase (P < 0.05 compared with Canola and CanolaDHA) and highest after the CanolaDHA phase (P < 0.05 compared with CornSaff, FlaxSaff, and CanolaOleic). Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were highest, and triglycerides were lowest, after CanolaDHA (P < 0.05 compared with the other diets). All diets decreased TC and LDL cholesterol from baseline to treatment endpoint (P < 0.05). CanolaDHA was the only diet that increased HDL cholesterol from baseline (3.5 ± 1.8%; P < 0.05) and produced the greatest reduction in triglycerides (-20.7 ± 3.8%; P < 0.001) and in systolic blood pressure (-3.3 ± 0.8%; P < 0.001) compared with the other diets (P < 0.05). Percentage reductions in Framingham 10-y CHD risk scores (FRS) from baseline were greatest after CanolaDHA (-19.0 ± 3.1%; P < 0.001) than after other treatments (P < 0.05).
Conclusion
Consumption of CanolaDHA, a novel DHA-rich canola oil, improves HDL cholesterol, triglycerides, and blood pressure, thereby reducing FRS compared with other oils varying in unsaturated fatty acid composition. This trial was registered at www.clinicaltrials.gov as NCT01351012.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.